Maher-Edwards G, De'Ath J, Barnett C, Lavrov A, Lockhart A (2015) <br />A 24-week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease<br /><i>Alzheimers Dement (N Y)</i> <b>1</b>: 131<br /><br />Fitzpatrick AL, Irizarry MC, Cushman M, Jenny NS, Chi GC, Koro C (2014) <br />Lipoprotein-associated phospholipase A2 and risk of dementia in the Cardiovascular Health Study<br /><i>Atherosclerosis</i> <b>235</b>: 384<br /><br />Shaddinger BC, Xu Y, Roger JH, Macphee CH, Handel M, Baidoo CA, Magee M, Lepore JJ, Sprecher DL (2014) <br />Platelet aggregation unchanged by lipoprotein-associated phospholipase A inhibition: results from an in vitro study and two randomized phase I trials<br /><i>PLoS ONE</i> <b>9</b>: e83094<br /><br />Tawakol A, Singh P, Rudd JH, Soffer J, Cai G, Vucic E, Brannan SP, Tarka EA, Shaddinger BC, Sarov-Blat L, Matthews P, Subramanian S, Farkouh M, Fayad ZA (2014) <br />Effect of treatment for 12 weeks with rilapladib, a lipoprotein-associated phospholipase A2 inhibitor, on arterial inflammation as assessed with 18F-fluorodeoxyglucose-positron emission tomography imaging<br /><i>J Am Coll Cardiol</i> <b>63</b>: 86<br /><br />Davidson JE, Lockhart A, Amos L, Stirnadel-Farrant HA, Mooser V, Sollberger M, Regeniter A, Monsch AU, Irizarry MC (2012) <br />Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study<br /><i>Alzheimers Res Ther</i> <b>4</b>: 51<br /><br />Wilensky RL, Macphee CH (2009) <br />Lipoprotein-associated phospholipase A(2) and atherosclerosis<br /><i>Curr Opin Lipidol</i> <b>20</b>: 415<br /><br />